# Vyome Holdings, Inc: overview HIND · Nasdaq · CIK 1427570 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/hind.md) · [Financials](/companies/hind/financials.md) · [Filings](/companies/hind/filings.md) · [Insiders](/companies/hind/insiders.md) Latest reported revenue: [$27.0k](/filings/0001213900-26-088402.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-088402). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,292](/filings/0001558370-24-015732.md) | [1,805 d](/filings/0001558370-25-004477.md) | [1,113](/filings/0001558370-25-008031.md) | [1,242](/filings/0001558370-25-011594.md) | [34.6](/filings/0001213900-25-110980.md) | [36.6 d](/filings/0001213900-26-029500.md) | [31.6](/filings/0001213900-26-055058.md) | [27.0](/filings/0001213900-26-088402.md) | | Gross margin | % | [1.6%](/filings/0001213900-25-110980.md) | [3.5% d](/filings/0001213900-26-029500.md) | [13.9%](/filings/0001213900-26-055058.md) | [2.0%](/filings/0001213900-26-088402.md) | [52.1%](/filings/0001213900-25-110980.md) | [60.4% d](/filings/0001213900-26-029500.md) | [52.7%](/filings/0001213900-26-055058.md) | [43.2%](/filings/0001213900-26-088402.md) | | Operating margin | % | [(12.3%)](/filings/0001213900-25-110980.md) | [(14.2%) d](/filings/0001213900-26-029500.md) | [(17.9%)](/filings/0001213900-26-055058.md) | [(26.1%)](/filings/0001213900-26-088402.md) | [(24761.9%)](/filings/0001213900-25-110980.md) | [(3707.4%) d](/filings/0001213900-26-029500.md) | [(3576.8%)](/filings/0001213900-26-055058.md) | [(3200.0%)](/filings/0001213900-26-088402.md) | | Net margin | % | [(23.9%)](/filings/0001213900-25-110980.md) | [(17.0%) d](/filings/0001213900-26-029500.md) | [(26.4%)](/filings/0001213900-26-055058.md) | [(24.9%)](/filings/0001213900-26-088402.md) | [(24356.2%)](/filings/0001213900-25-110980.md) | [(3352.7%) d](/filings/0001213900-26-029500.md) | [(3048.1%)](/filings/0001213900-26-055058.md) | [(2543.3%)](/filings/0001213900-26-088402.md) | | Diluted EPS | $ per share | [(1419.10)](/filings/0001213900-25-110980.md) | not reported | [(761.59)](/filings/0001213900-26-055058.md) | [(799.90)](/filings/0001213900-26-088402.md) | [(3.12)](/filings/0001213900-25-110980.md) | not reported | [(0.15)](/filings/0001213900-26-055058.md) | [(0.10)](/filings/0001213900-26-088402.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [13.6](/filings/0001558370-23-006079.md) | [11.2](/filings/0001558370-24-004559.md) | [8.7](/filings/0001558370-25-004477.md) | [8.0](/filings/0001558370-25-004477.md) | [0.3](/filings/0001213900-26-029500.md) | | Gross margin | % | [61.4%](/filings/0001558370-23-006079.md) | [60.5%](/filings/0001558370-24-004559.md) | [63.9%](/filings/0001558370-25-004477.md) | [2.4%](/filings/0001213900-26-029500.md) | [68.4%](/filings/0001213900-26-029500.md) | | Operating margin | % | [(425.6%)](/filings/0001558370-23-006079.md) | [(412.4%)](/filings/0001558370-24-004559.md) | [(177.3%)](/filings/0001558370-25-004477.md) | [(12.6%)](/filings/0001213900-26-029500.md) | [(3269.4%)](/filings/0001213900-26-029500.md) | | Net margin | % | [(464.3%)](/filings/0001558370-23-006079.md) | [(411.2%)](/filings/0001558370-24-004559.md) | [(131.2%)](/filings/0001558370-25-004477.md) | [(18.1%)](/filings/0001213900-26-029500.md) | [(3209.7%)](/filings/0001213900-26-029500.md) | | Diluted EPS | $ per share | [(288.97)](/filings/0001558370-23-006079.md) | [(108.90)](/filings/0001558370-24-004559.md) | [(110.87)](/filings/0001558370-25-004477.md) | [(6001.39)](/filings/0001213900-26-029500.md) | [(4.86)](/filings/0001213900-26-029500.md) | | Free cash flow | $m | [(15.7)](/filings/0001558370-23-006079.md) | [(22.0)](/filings/0001558370-24-004559.md) | [(17.0)](/filings/0001558370-25-004477.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hind/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $55.8k | 25,972 | | New +25,972 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $55.5k | 25,793 | | Unchanged | | [Focus Partners Wealth](/funds/1542153.md) | 2026-06-30 | $31.5k | 14,640 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $26.2k | 12,195 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $25.6k | 11,908 | | Reduced −10,767 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $21.6k | 10,058 | | New +10,058 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $20.3k | 9,463 | | Unchanged | | [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $13.0k | 5,856 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.9k | 1,808 | | Added +417 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $56 | 26 | | New +26 | ## Recent filings [All 690 filings](/companies/hind/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-28 | 16:31 ET | [8-K](/filings/0001213900-26-095093.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-095093 | | 2026-08-25 | 16:05 ET | [8-K](/filings/0001213900-26-093512.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-093512 | | 2026-08-12 | 16:32 ET | [10-Q](/filings/0001213900-26-088402.md) | Quarterly report, period 2026-06-30 | 0001213900-26-088402 | | 2026-05-29 | 08:42 ET | [8-K](/filings/0001213900-26-062458.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-062458 | | 2026-05-12 | 16:03 ET | [10-Q](/filings/0001213900-26-055058.md) | Quarterly report, period 2026-03-31 | 0001213900-26-055058 | | 2026-04-29 | 16:16 ET | [8-K](/filings/0001213900-26-049312.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-049312 | | 2026-03-31 | 06:03 ET | [DEF 14A](/filings/0001213900-26-036740.md) | Proxy statement, period 2026-04-24 | 0001213900-26-036740 | | 2026-03-18 | 06:38 ET | [10-K](/filings/0001213900-26-029500.md) | Annual report, period 2025-12-31 | 0001213900-26-029500 | | 2026-02-25 | 16:15 ET | [8-K](/filings/0001213900-26-020387.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-020387 | | 2026-02-13 | 21:16 ET | [8-K](/filings/0001213900-26-015795.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-015795 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-029500.md), filed Mar 18, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b01de577-5d5f-43f3-9246-fde03f9cdcb4) ## About the filer - CIK: 1427570 - Tickers: HIND - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.